111641-17-9

Basic information

• Product Name: 4-(PIPERAZIN-1-YL)-2,6-DI-(PYRROLIDIN-1-YL)-PYRIMIDINE
• Synonyms: 4-(PIPERAZIN-1-YL)-2,6-DI-(PYRROLIDIN-1-YL)-PYRIMIDINE;4-(PIPERAZIN-1-YL)-2,6-BIS(PYRROLIDIN-1-YL)PYRIMIDINE
• CAS NO: 111641-17-9
• Molecular Formula: C₁₆H₂₆N₆
• Molecular Weight: 302.42
• Product Categories: pharmacetical
• Mol File: 111641-17-9.mol

Chemical Properties

• Melting Point: 177-178 °C
• Boiling Point: 553.2°Cat760mmHg
• Flash Point: 288.4°C
• Appearance: /
• Density: 1.194g/cm³
• Vapor Pressure: 2.78E-12mmHg at 25°C
• Refractive Index: 1.597
• PKA: 12.04±0.50(Predicted)
• CAS DataBase Reference: 4-(PIPERAZIN-1-YL)-2,6-DI-(PYRROLIDIN-1-YL)-PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PIPERAZIN-1-YL)-2,6-DI-(PYRROLIDIN-1-YL)-PYRIMIDINE(111641-17-9)
• EPA Substance Registry System: 4-(PIPERAZIN-1-YL)-2,6-DI-(PYRROLIDIN-1-YL)-PYRIMIDINE(111641-17-9)

Safety Data

• Hazardous Substances Data: 111641-17-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H26N6/c1-2-8-20(7-1)14-13-15(21-11-5-17-6-12-21)19-16(18-14)22-9-3-4-10-22/h13,17H,1-12H2

Upstream product

• 79-37-8 oxalyl dichloride 
• 13427-53-7 4-(2-hydroxyethoxy)-phenol 
• 110-85-0 piperazine 
• 111669-15-9 2,4-di(1-pyrrolidinyl)-6-chloropyrimidine 
• 123-75-1 pyrrolidine 
• 3764-01-0 2,4,6-trichloropyrimidine 

Downstream Products

• 159872-32-9 1-(10-undecenoyl)-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine 
• 110101-66-1 16α-methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione 

Relevant articles and documents

Highly selective hydrolysis of chloropyrimidines to pyrimidones in 12 N hydrochloric acid

A chromatography-free process for synthesis of 6-piperazinyl-2,4-bis- pyrrolidinylpyrimidine in isomerically pure form is described. The key step is the purification of a crude 6-chloro-2,4-bis-pyrrolidinylpyrimidine/2-chloro-4, 6-bis-pyrrolidinylpyrimidine isomer mixture (generated by reaction of 2,4,6-trichloropyrimidine with pyrrolidine) by a highly selective acid-catalyzed hydrolysis of the 2-chloro isomer to the pyrimidone. The 2-chloro isomer hydrolyzes 350 times faster than the 6-chloro isomer in 6 N HCl and 1750 times faster in 12 N HCl. To put these rate ratios in perspective, the 2-chloro isomer reacts with amines and alkoxides only ～ 10-17 times faster than does the 6-chloro isomer. A mechanistic investigation using methodological tools developed by Bunnett established that the transition state for hydrolysis of the 6-chloro isomer involves two more molecules of water (each acting as a base) than does the transition state for hydrolysis of the 2-chloro isomer. As the concentration of HCl increases from 3 N to 6 N to 12 N, there are fewer unprotonated water molecules. Thus, the transition state that involves the greater number of unprotonated water molecules (6-chloro-2,4-bis- pyrrolidinylpyrimidine) is expected to be increasingly disfavored with increasing acid concentration, as is observed. The optimized process was run successfully on production scale.

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Pharmaceutically active amines

The aromatic amines (I), alkyl amines (II), bicyclic amines (III). STR1 cycloalkyl amines (IV), aromatic bicyclic amines (V), hydroquinone amines (VI), quinone amines (VII), amino-ethers (VIII) and bicyclic amino ethers (IX) are useful as pharmaceutical agents for treating a number of conditions including spinal trauma, mild and/or moderate to severe head injury, etc. Also disclosed is a method of treatment using the 3,4-dihydrobenzopyrans (XI).

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke

The amino-9,10-secosteroids STR1 of the present invention contain an amino group attached to the terminal carbon atom of the C17 -side chain and are useful as pharmaceutical agents for treating a number of conditions including spinal trauma, mild and/or moderate to severe head injury, etc.

Novel 21-Aminosteroids That Inhibit Iron-Dependent Lipid Peroxidation and Protect against Central Nervous System Trauma

A novel class of 21-aminosteroids has been developed.Compounds within this series are potent inhibitors of iron-dependent lipid peroxidation in rat brain homogenates with IC50's as low as 3 μM.Furthermore, selected members enhance early neurolo

C20 Through C26 amino steroids

Disclosed are Δ9 (11)-steroids (VI) and amino substituted steroids of formula (XI) which contain an amino group attached to the terminal carbon atom of the C17-side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 (11)-steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17 (20)-steroids (Va and Vb) and Δ9 (11)-steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.